View Older Stories
-
Repligen launches three new chromatography resins for gene therapy
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Repligen (RGEN): No reason to change bullish stance on stock, says Stifel
-
Repligen (RGEN) PT Raised to $160 at Jefferies
-
Repligen (RGEN) Tops Q3 EPS by 4c ; Offers Guidance
-
HSBC Starts Repligen (RGEN) at Buy
-
KeyBanc Takeaways from This Year's BioProcess International Conference
-
KeyBanc Reiterates Overweight Rating on Repligen (RGEN)
-
Evercore ISI Upgrades Repligen (NASDAQ: RGEN) to Outperform (correction)
-
TD Cowen Reiterates Buy Rating on Repligen (RGEN), Still a Top Pick
-
Stifel Reiterates Buy Rating on Repligen (RGEN)
-
Repligen (RGEN) PT Lowered to $135 at Jefferies
-
H.C. Wainwright Reiterates Buy Rating on Repligen (RGEN)
-
KeyBanc Reiterates Overweight Rating on Repligen (RGEN)
-
Repligen (RGEN) Misses Q2 EPS by 2c; offers guidance
-
Barclays Starts Repligen (RGEN) at Overweight
-
908 Devices (MASS) Appoints Christopher D. Brown to its Board of Directors
-
Maravai LifeSciences (MRVI) on watch on vague chatter following CEO change
-
Repligen (RGEN) Trading LOD, Down 3.6pct
-
Repligen (RGEN) PT Lowered to $940 at Truist Securities
-
Repligen (RGEN) PT Lowered to $914 at Jefferies
-
Repligen (RGEN) PT Lowered to $190 at JPMorgan, 'All in, we applaud RGEN’s consistent performance during the bioprocessing recovery'
-
Repligen (RGEN) Tops Q1 EPS by 4c, provides guidance
-
Evercore ISI Starts Repligen (RGEN) at In Line
-
Leerink Partners Reiterates Outperform Rating on Repligen (RGEN)
-
Repligen (RGEN) Purchases Bioprocessing Analytics Portfolio from 908 Devices (MASS)
-
TD Cowen Issues Stock Conclusions Following Bioproduction Market Survey
-
Benchmark Reiterates Hold Rating on Repligen (RGEN)
-
H.C. Wainwright Reiterates Buy Rating on Repligen (RGEN)
-
Repligen (RGEN) PT Raised to $170 at Canaccord Genuity
-
KeyBanc Reiterates Overweight Rating on Repligen (RGEN)
-
Repligen (RGEN) PT Raised to $165 at Jefferies
-
Repligen (RGEN) Tops Q4 EPS by 3c ; Offers Guidance
-
TD Cowen Starts Repligen (RGEN) at Buy
-
Repligen (RGEN) Launches the CTech SoloVPE PLUS System
-
Canaccord Genuity Starts Repligen (RGEN) at Hold
-
Repligen (RGEN) Launches Novel AVIPure dsRNA Resin in OPUS® Pre-packed Columns
-
Wolfe Research Starts Repligen (RGEN) at Peerperform
-
KeyBanc Reiterates Overweight Rating on Repligen (RGEN)
-
Repligen (RGEN) Tops Q3 EPS by 10c ; Offers Guidance
-
After-hours movers: Steelcase, Hess Midstream Partners, Repligen
-
Repligen (RGEN) Reports Non-Reliance on Previously Issued Financial Statements
-
KeyBanc Reiterates Overweight Rating on Repligen (RGEN)
-
Stifel on Repligen (RGEN) M&A Speculation with Maravai (MRVI)
-
Midday movers: H&R Block, Maravai LifeSciences rise; Applied Materials falls
-
Repligen (RGEN) Has Approached Maravai Lifesciences (MRVI) with an Acquisition Offer - Reuters
-
Repligen (RGEN) Reports In-Line Q2 EPS, provides guidance
-
Repligen (RGEN) to Acquire Chromatography Innovator Tantti
-
Repligen (RGEN) discoveres unauthorized third party had accessed certain files on the Company’s information systems
-
Deutsche Bank New Quarterly Feature Called 'Fresh Money List' Picks, 17 Additions

